Table 3.
Symptoms and diagnostic tests according to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) seroprevalence and symptoms in Manaus, Amazonas, Brazil.
| Characteristics | Variables | Total | Column % | IgG positive | Prevalencerow % | P-valueχ2 test | IgG positive and symptomsb | Prevalencerow % | P-valueχ2 test |
|---|---|---|---|---|---|---|---|---|---|
| Total | 3046 | 886 | 29.10 | 725 | 23.84 | ||||
| Symptoms | |||||||||
| Flu-like symptoms in last 7 days | No | 2479 | 82.61 | 716 | 28.89 | 0.474 | — | — | |
| Yes | 522 | 17.39 | 159 | 30.46 | |||||
| Flu-like symptoms since March (any) | No | 685 | 22.52 | 163 | 23.80 | 0.001 | — | — | |
| Yes | 2357 | 77.48 | 722 | 30.65 | |||||
| Which symptoms | Anosmia | 525 | 22.27 | 341 | 64.95 | <0.001 | — | — | |
| Body aches | 971 | 41.20 | 372 | 38.35 | <0.001 | — | — | ||
| Chest pain | 337 | 14.30 | 138 | 41.07 | <0.001 | — | — | ||
| Chills | 343 | 14.55 | 156 | 45.48 | <0.001 | — | — | ||
| Conjunctivitis | 61 | 2.59 | 19 | 31.15 | 0.200 | — | — | ||
| Cough | 842 | 35.72 | 304 | 36.10 | <0.001 | — | — | ||
| Diarrhoea | 655 | 27.79 | 206 | 31.45 | 0.002 | — | — | ||
| Fever | 717 | 30.42 | 318 | 44.41 | <0.001 | — | — | ||
| Headache | 1633 | 69.28 | 508 | 31.13 | <0.001 | — | — | ||
| Lack of appetite | 339 | 14.38 | 178 | 52.66 | <0.001 | — | — | ||
| Palpitations | 239 | 10.14 | 76 | 31.80 | 0.015 | — | — | ||
| Shortness of breath | 487 | 20.66 | 175 | 35.93 | <0.001 | — | — | ||
| Side chest pain | 612 | 25.97 | 224 | 36.66 | <0.001 | — | — | ||
| Skin rashes | 130 | 5.52 | 45 | 34.62 | 0.009 | — | — | ||
| Sore throat | 1049 | 44.51 | 315 | 30.06 | 0.004 | — | — | ||
| Vomiting | 140 | 5.94 | 44 | 31.43 | <0.001 | — | — | ||
| Prior COVID-19 diagnosis | |||||||||
| Prior SARS-CoV-2 RT-PCR | No | 2788 | 92.35 | 798 | 28.63 | <0.001 | 647 | 23.21 | <0.001 |
| Yes, negative | 172 | 5.70 | 40 | 23.26 | 36 | 20.93 | |||
| Yes, positive | 59 | 1.95 | 42 | 71.19 | 37 | 62.71 | |||
| Prior serological test | No | 2349 | 77.76 | 660 | 28.11 | <0.001 | 528 | 22.49 | <0.001 |
| Yes, negative | 531 | 17.58 | 116 | 21.85 | 103 | 19.40 | |||
| Yes, positive | 141 | 4.67 | 103 | 73.05 | 89 | 63.12 | |||
| Prior COVID-19 diagnosisc | No | 2771 | 91.72 | 728 | 26.28 | <0.001 | 588 | 21.23 | <0.001 |
| Yes | 250 | 8.28 | 154 | 61.60 | 135 | 54.00 | |||
| Took medications after COVID-19 diagnosis | No | 109 | 43.60 | 51 | 46.79 | <0.001 | 43 | 39.45 | <0.001 |
| Yes | 141 | 56.40 | 103 | 73.05 | 92 | 65.25 | |||
| Which medications | Nitazoxanide | 11 | 7.80 | 10 | 90.91 | 0.008a | 10 | 90.91 | 0.002a |
| Azithromycin | 108 | 76.60 | 78 | 72.22 | <0.001 | 70 | 64.81 | <0.001 | |
| Hydroxy/chloroquine | 27 | 19.15 | 19 | 70.37 | 0.028 | 17 | 62.96 | 0.028 | |
| Corticosteroids | 36 | 25.53 | 28 | 77.78 | 0.001 | 26 | 72.22 | 0.001 | |
| Ivermectin | 77 | 54.61 | 52 | 67.53 | 0.005 | 47 | 61.04 | 0.004 | |
| Paracetamol | 59 | 41.84 | 46 | 77.97 | <0.001 | 44 | 74.58 | <0.001 | |
| Others | 38 | 26.95 | 28 | 73.68 | 0.004 | 25 | 65.79 | 0.005 | |
IgG, immunoglobulin G; COVID-19, coronavirus disease 2019; RT-PCR, reverse transcriptase polymerase chain reaction.
Fisher´s exact test.
Participants who had both SARS-CoV-2 IgG positive test and reported symptoms prior to recruitment since March 2020.
Previous COVID-19 diagnosis was defined as individuals positive for SARS-CoV-2 RT-PCR or SARS-CoV-2 serological test or clinical diagnosis as COVID-19.